Drugs / ZANSECIMAB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02597036 | Nov 2015 → Nov 2017 | cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04342897 | Apr → Oct 2020 | COVID-19, pneumonia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZANSECIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650486 ↗ |
| Known as | LY3127804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02597036 ↗ |
| Action | Inhibit | “anti-angiopoietin-2 (Ang-2)” PMID 32741971 ↗ Aug 20201“Angiopoietin-2 inhibitor” CHEMBL4650486 ↗ |
| Modality | Monoclonal antibody | “anti-angiopoietin-2 (Ang-2) monoclonal antibody” PMID 32741971 ↗ Aug 2020 |
| Route | Intravenous | “Administered IV” NCT02597036 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL4650486 ↗ |